At a remarkably low price, are these two disappointing individuals still a potential threat?
Revamped Review:
Cheap Stocks Aren't Always a Bargain: A Closer Look at PepsiCo and Moderna
Same scene at the stock exchange, huh? Are we snagging cheap wins with these two underperformers, or are they just pitiful losers? Let's dig in.
Can PepsiCo Rebound?
If you're eyeing PepsiCo's ticker at around 154 bucks, you'll notice it's hardly seen such lows since 2021. The steep drop since late '24 is no accident - it's due to slumping consumer interest, which dampened the impact of price hikes.
In the short term, discerning investors shouldn't expect a grand comeback from PepsiCo. But in the long run, with its globally recognized lineup of snacks and beverages, the company could pull off a turnaround. And here's the cherry on top - PepsiCo is a dividend champion, consistently upping payouts to shareholders for 52 years. That generous 3.5% dividend yield is quite the tempting supplement for a defensive portfolio. Oh, and did we mention PepsiCo pops up in the BÖRSE ONLINE Agriculture and Food Index?
PepsiCo (WKN: 851995)
Is Moderna Salvageable?
Compared to PepsiCo, Moderna's position appears more precarious. Its stock is hanging on at levels similar to April '20, having shed most pandemic-era gains. Figuring out the company's true value right now can be a challenge.
Moderna is currently belt-tightening, having recently cut its 2025 outlook. Although losses shrank last year, there's no apparent blockbuster to fuel future profits yet. Moderna does dabble in cancer therapies, a promising market where the stock might find some traction. Overall, this baby's a hot potato. Investors need to exercise patience and monitor Moderna's financials closely. But hey, if a major virus outbreak like avian flu sparks a need for a new vaccine, things could change in the blink of an eye. Even then, Moderna wouldn't be the only player in the game. The outcome remains uncertain.
Moderna Inc (WKN: A2N9D9)
Dive-Deep:
- Read Up: Over 280% upside: Is this biotech secret tip now better than BioNTech and Co?
- Keep Tabs: During DeepSeek storms: Cathie Wood quickly struck at this famous tech giant
Disclosure: The displayed securities' prices stem from an index used as the underlying. Boersenmedien AG has developed this index and holds the rights to it. Boersenmedien AG has entered into a cooperation agreement with the issuer of these securities, granting said issuer a license to use the index. In this instance, Boersenmedien AG receives payment from the issuer.
In the short term, while PepsiCo may not see a significant rebound, its globally recognized product lineup and consistent dividend payouts make it an attractive option for long-term investors. On the other hand, Moderna's current financial situation seems challenging, and investors must exercise patience, keeping a close eye on its financials, as a major virus outbreak could potentially change its fortunes, albeit with uncertainty about its position among competitors.
